These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
x
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
o
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
Delaware
|
|
82-4979096
|
|
(State or other Jurisdiction of
|
|
(I.R.S. Employer
|
|
Incorporation or Organization)
|
|
Identification No.)
|
|
Large Accelerated Filer
x
|
|
Accelerated Filer
o
|
|
|
|
|
|
Non-Accelerated Filer
o
|
|
Smaller reporting company
o
|
|
|
|
|
|
|
|
Emerging growth company
o
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Common Stock, par value $0.01 per share
|
|
CTVA
|
|
New York Stock Exchange
|
|
|
|
Page
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|||
|
|
|
|
|
|
|
|
|
|
|
|
|||
|
|
|
|
|
|
|
|||
|
|
|||
|
Item 1.
|
CONSOLIDATED FINANCIAL STATEMENTS
|
|
(In millions)
|
Three Months Ended March 31,
|
|||||
|
|
2019
|
2018
|
||||
|
Net sales
|
$
|
6,288
|
|
$
|
6,699
|
|
|
Cost of goods sold
|
4,235
|
|
4,847
|
|
||
|
Research and development expense
|
355
|
|
382
|
|
||
|
Selling, general and administrative expenses
|
970
|
|
959
|
|
||
|
Amortization of intangibles
|
320
|
|
315
|
|
||
|
Restructuring and asset related charges - net
|
55
|
|
97
|
|
||
|
Integration and separation costs
|
405
|
|
255
|
|
||
|
Sundry income - net
|
157
|
|
47
|
|
||
|
Interest expense
|
56
|
|
80
|
|
||
|
Income (loss) from continuing operations before income taxes
|
49
|
|
(189
|
)
|
||
|
(Benefit from) provision for income taxes on continuing operations
|
(40
|
)
|
27
|
|
||
|
Income (loss) from continuing operations after income taxes
|
89
|
|
(216
|
)
|
||
|
Loss from discontinued operations after income taxes
|
—
|
|
(5
|
)
|
||
|
Net income (loss)
|
89
|
|
(221
|
)
|
||
|
Net income attributable to noncontrolling interests
|
4
|
|
7
|
|
||
|
Net income (loss) attributable to Historical DuPont
|
$
|
85
|
|
$
|
(228
|
)
|
|
(In millions)
|
Three Months Ended March 31,
|
|||||
|
|
2019
|
2018
|
||||
|
Net income (loss)
|
$
|
89
|
|
$
|
(221
|
)
|
|
Other comprehensive (loss) income - net of tax:
|
|
|
||||
|
Cumulative translation adjustments
|
(68
|
)
|
957
|
|
||
|
Adjustments to pension benefit plans
|
(6
|
)
|
4
|
|
||
|
Derivative instruments
|
1
|
|
11
|
|
||
|
Total other comprehensive (loss) income
|
(73
|
)
|
972
|
|
||
|
Comprehensive income
|
16
|
|
751
|
|
||
|
Comprehensive income attributable to noncontrolling interests - net of tax
|
4
|
|
7
|
|
||
|
Comprehensive income attributable to Historical DuPont
|
$
|
12
|
|
$
|
744
|
|
|
(In millions, except share amounts)
|
March 31, 2019
|
December 31, 2018
|
||||
|
Assets
|
|
|
|
|
||
|
Current assets
|
|
|
|
|
||
|
Cash and cash equivalents
|
$
|
3,796
|
|
$
|
4,466
|
|
|
Marketable securities
|
18
|
|
34
|
|
||
|
Accounts and notes receivable - net
|
6,768
|
|
5,534
|
|
||
|
Inventories
|
7,147
|
|
7,407
|
|
||
|
Other current assets
|
1,515
|
|
1,165
|
|
||
|
Total current assets
|
19,244
|
|
18,606
|
|
||
|
Investment in nonconsolidated affiliates
|
1,366
|
|
1,381
|
|
||
|
Property, plant and equipment - net of accumulated depreciation (March 31, 2019 - $2,111; December 31, 2018 - $1,720)
|
12,083
|
|
12,186
|
|
||
|
Goodwill
|
40,638
|
|
40,686
|
|
||
|
Other intangible assets
|
25,724
|
|
26,053
|
|
||
|
Deferred income taxes
|
306
|
|
303
|
|
||
|
Other assets
|
2,476
|
|
1,810
|
|
||
|
Total Assets
|
$
|
101,837
|
|
$
|
101,025
|
|
|
Liabilities and Equity
|
|
|
|
|
||
|
Current liabilities
|
|
|
|
|
||
|
Short-term borrowings and finance lease obligations
|
$
|
3,205
|
|
$
|
2,160
|
|
|
Accounts payable
|
4,200
|
|
4,982
|
|
||
|
Income taxes payable
|
137
|
|
66
|
|
||
|
Accrued and other current liabilities
|
4,400
|
|
4,233
|
|
||
|
Total current liabilities
|
11,942
|
|
11,441
|
|
||
|
Long-Term Debt
|
6,320
|
|
5,812
|
|
||
|
Other Noncurrent Liabilities
|
|
|
||||
|
Deferred income tax liabilities
|
5,164
|
|
5,381
|
|
||
|
Pension and other post employment benefits - noncurrent
|
6,524
|
|
6,683
|
|
||
|
Other noncurrent obligations
|
2,052
|
|
1,620
|
|
||
|
Total noncurrent liabilities
|
20,060
|
|
19,496
|
|
||
|
Commitments and contingent liabilities
|
|
|
||||
|
Stockholders’ equity
|
|
|
|
|
||
|
Preferred stock, without par value – cumulative; 23,000,000 shares authorized;
issued at March 31, 2019 and December 31, 2018:
|
|
|
||||
|
$4.50 Series – 1,673,000 shares (callable at $120)
|
169
|
|
169
|
|
||
|
$3.50 Series – 700,000 shares (callable at $102)
|
70
|
|
70
|
|
||
|
Common stock, $0.30 par value; 1,800,000,000 shares authorized;
issued at March 31, 2019 and December 31, 2018 - 100
|
—
|
|
—
|
|
||
|
Additional paid-in capital
|
79,843
|
|
79,790
|
|
||
|
Accumulated deficit
|
(7,906
|
)
|
(7,669
|
)
|
||
|
Accumulated other comprehensive loss
|
(2,576
|
)
|
(2,503
|
)
|
||
|
Total Historical DuPont stockholders’ equity
|
69,600
|
|
69,857
|
|
||
|
Noncontrolling interests
|
235
|
|
231
|
|
||
|
Total equity
|
69,835
|
|
70,088
|
|
||
|
Total Liabilities and Equity
|
$
|
101,837
|
|
$
|
101,025
|
|
|
(In millions)
|
Three Months Ended March 31,
|
|||||
|
|
2019
|
2018
|
||||
|
Operating activities
|
|
|
||||
|
Net income (loss)
|
$
|
89
|
|
$
|
(221
|
)
|
|
Adjustments to reconcile net income (loss) to cash used for operating activities:
|
|
|
|
|
||
|
Depreciation and amortization
|
678
|
|
647
|
|
||
|
(Benefit from) provision for deferred income tax
|
(233
|
)
|
35
|
|
||
|
Net periodic pension benefit
|
(70
|
)
|
(79
|
)
|
||
|
Pension contributions
|
(50
|
)
|
(70
|
)
|
||
|
Net gain on sales of property, businesses, consolidated companies, and investments
|
(55
|
)
|
(2
|
)
|
||
|
Restructuring and asset related charges - net
|
55
|
|
97
|
|
||
|
Amortization of inventory step-up
|
205
|
|
703
|
|
||
|
Other net loss
|
72
|
|
258
|
|
||
|
Changes in operating assets and liabilities - net
|
(2,113
|
)
|
(3,343
|
)
|
||
|
Cash used for operating activities
|
(1,422
|
)
|
(1,975
|
)
|
||
|
Investing activities
|
|
|
|
|||
|
Capital expenditures
|
(625
|
)
|
(355
|
)
|
||
|
Proceeds from sales of property, businesses, and consolidated companies - net of cash divested
|
100
|
|
18
|
|
||
|
Purchases of investments
|
(16
|
)
|
(201
|
)
|
||
|
Proceeds from sales and maturities of investments
|
32
|
|
922
|
|
||
|
Other investing activities - net
|
(5
|
)
|
(2
|
)
|
||
|
Cash (used for) provided by investing activities
|
(514
|
)
|
382
|
|
||
|
Financing activities
|
|
|
|
|||
|
Change in short-term (less than 90 days) borrowings
|
815
|
|
(97
|
)
|
||
|
Proceeds from issuance of long-term debt
|
1,000
|
|
253
|
|
||
|
Payments on long-term debt
|
(283
|
)
|
(31
|
)
|
||
|
Proceeds from exercise of stock options
|
35
|
|
45
|
|
||
|
Dividends paid to stockholders
|
(2
|
)
|
(2
|
)
|
||
|
Distributions to DowDuPont
|
(317
|
)
|
(830
|
)
|
||
|
Other financing activities
|
(22
|
)
|
(32
|
)
|
||
|
Cash provided by (used for) financing activities
|
1,226
|
|
(694
|
)
|
||
|
Effect of exchange rate changes on cash, cash equivalents and restricted cash
|
20
|
|
108
|
|
||
|
Decrease in cash, cash equivalents and restricted cash
|
(690
|
)
|
(2,179
|
)
|
||
|
Cash, cash equivalents and restricted cash at beginning of period
|
4,966
|
|
7,808
|
|
||
|
Cash, cash equivalents and restricted cash at end of period
|
$
|
4,276
|
|
$
|
5,629
|
|
|
(In millions)
|
Preferred Stock
|
Additional Paid-in Capital
|
Retained Earnings (Accumulated Deficit)
|
Accumulated Other Comp Inc (Loss)
|
Non-controlling Interests
|
Total Equity
|
||||||||||||
|
Balance at January 1, 2018
|
$
|
239
|
|
$
|
74,727
|
|
$
|
175
|
|
$
|
(381
|
)
|
$
|
172
|
|
$
|
74,932
|
|
|
Net income
|
—
|
|
—
|
|
(228
|
)
|
—
|
|
7
|
|
(221
|
)
|
||||||
|
Other comprehensive income
|
—
|
|
—
|
|
—
|
|
972
|
|
—
|
|
972
|
|
||||||
|
Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)
|
—
|
|
—
|
|
(2
|
)
|
—
|
|
—
|
|
(2
|
)
|
||||||
|
Distributions to DowDuPont
|
—
|
|
—
|
|
(831
|
)
|
—
|
|
—
|
|
(831
|
)
|
||||||
|
Issuance of DowDuPont stock
|
—
|
|
45
|
|
—
|
|
—
|
|
—
|
|
45
|
|
||||||
|
Stock-based compensation
|
—
|
|
11
|
|
—
|
|
—
|
|
—
|
|
11
|
|
||||||
|
Other
|
—
|
|
—
|
|
5
|
|
—
|
|
55
|
|
60
|
|
||||||
|
Balance at March 31, 2018
|
$
|
239
|
|
$
|
74,783
|
|
$
|
(881
|
)
|
$
|
591
|
|
$
|
234
|
|
$
|
74,966
|
|
|
(In millions)
|
Preferred Stock
|
Additional Paid-in Capital
|
Accumulated Deficit
|
Accumulated Other Comp Loss
|
Non-controlling Interests
|
Total Equity
|
||||||||||||
|
Balance at January 1, 2019
|
$
|
239
|
|
$
|
79,790
|
|
$
|
(7,669
|
)
|
$
|
(2,503
|
)
|
$
|
231
|
|
$
|
70,088
|
|
|
Net income
|
—
|
|
—
|
|
85
|
|
—
|
|
4
|
|
89
|
|
||||||
|
Other comprehensive loss
|
—
|
|
—
|
|
—
|
|
(73
|
)
|
—
|
|
(73
|
)
|
||||||
|
Preferred dividends ($4.50 Series - $1.125 per share, $3.50 Series - $0.875 per share)
|
—
|
|
—
|
|
(2
|
)
|
—
|
|
—
|
|
(2
|
)
|
||||||
|
Distributions to DowDuPont
|
—
|
|
—
|
|
(317
|
)
|
—
|
|
—
|
|
(317
|
)
|
||||||
|
Issuance of DowDuPont stock
|
—
|
|
35
|
|
—
|
|
—
|
|
—
|
|
35
|
|
||||||
|
Stock-based compensation
|
—
|
|
18
|
|
—
|
|
—
|
|
—
|
|
18
|
|
||||||
|
Other
|
—
|
|
—
|
|
(3
|
)
|
—
|
|
—
|
|
(3
|
)
|
||||||
|
Balance at March 31, 2019
|
$
|
239
|
|
$
|
79,843
|
|
$
|
(7,906
|
)
|
$
|
(2,576
|
)
|
$
|
235
|
|
$
|
69,835
|
|
|
|
E.I. du Pont de Nemours and Company
|
|
|
|
Notes to the Consolidated Financial Statements (Unaudited)
|
|
|
Note
|
|
Page
|
|
1
|
||
|
2
|
||
|
3
|
||
|
4
|
||
|
5
|
||
|
6
|
||
|
7
|
||
|
8
|
||
|
9
|
||
|
10
|
||
|
11
|
||
|
12
|
||
|
13
|
||
|
14
|
||
|
15
|
||
|
16
|
||
|
17
|
||
|
18
|
||
|
(In millions)
|
As Reported
December 31, 2018
|
Effect of Adoption of ASU 2016-02
|
Updated
January 1, 2019
|
||||||
|
Assets
|
|
|
|
||||||
|
Property, plant and equipment - net of accumulated depreciation
|
$
|
12,186
|
|
$
|
9
|
|
$
|
12,195
|
|
|
Other assets
|
$
|
1,810
|
|
$
|
758
|
|
$
|
2,568
|
|
|
|
|
|
|
||||||
|
Liabilities and Equity
|
|
|
|
||||||
|
Current liabilities
|
|
|
|
||||||
|
Short-term borrowings and finance lease obligations
|
$
|
2,160
|
|
$
|
1
|
|
$
|
2,161
|
|
|
Accrued and other current liabilities
|
$
|
4,233
|
|
$
|
234
|
|
$
|
4,467
|
|
|
|
|
|
|
||||||
|
Long-Term Debt
|
$
|
5,812
|
|
$
|
8
|
|
$
|
5,820
|
|
|
Other noncurrent obligations
|
$
|
1,620
|
|
$
|
524
|
|
$
|
2,144
|
|
|
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
Integration and separation costs
|
$
|
405
|
|
$
|
255
|
|
|
Contract Balances
|
March 31, 2019
|
December 31, 2018
|
||||
|
(In millions)
|
||||||
|
Accounts and notes receivable - trade
1
|
$
|
5,619
|
|
$
|
4,130
|
|
|
Contract assets - current
2
|
$
|
36
|
|
$
|
48
|
|
|
Deferred revenue - current
3
|
$
|
2,033
|
|
$
|
1,927
|
|
|
Deferred revenue - noncurrent
4
|
$
|
28
|
|
$
|
30
|
|
|
1.
|
Included in accounts and notes receivable - net in the Consolidated Balance Sheets.
|
|
2.
|
Included in other current assets in the Consolidated Balance Sheets.
|
|
3.
|
Included in accrued and other current liabilities in the Consolidated Balance Sheets.
|
|
4.
|
Included in other noncurrent obligations in the Consolidated Balance Sheets.
|
|
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
Agriculture
|
$
|
2,108
|
|
$
|
2,343
|
|
|
Packaging and Specialty Plastics
|
363
|
|
419
|
|
||
|
Electronics and Imaging
|
455
|
|
527
|
|
||
|
Nutrition and Health
|
1,014
|
|
1,024
|
|
||
|
Industrial Biosciences
|
376
|
|
406
|
|
||
|
Transportation and Advanced Polymers
|
1,071
|
|
1,121
|
|
||
|
Safety and Construction
|
899
|
|
855
|
|
||
|
Other
|
2
|
|
4
|
|
||
|
Total
|
$
|
6,288
|
|
$
|
6,699
|
|
|
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
U.S. & Canada
|
$
|
2,250
|
|
$
|
2,515
|
|
|
EMEA
1
|
2,110
|
|
2,166
|
|
||
|
Asia Pacific
|
1,459
|
|
1,535
|
|
||
|
Latin America
|
469
|
|
483
|
|
||
|
Total
|
$
|
6,288
|
|
$
|
6,699
|
|
|
1.
|
Europe, Middle East, and Africa ("EMEA").
|
|
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
Severance and related benefit costs
|
$
|
40
|
|
$
|
68
|
|
|
Contract termination charges
|
—
|
|
29
|
|
||
|
Asset related charges
|
16
|
|
—
|
|
||
|
Total restructuring and asset related charges - net
1
|
$
|
56
|
|
$
|
97
|
|
|
1.
|
The charge for the three months ended March 31, 2019 includes
$55 million
which was recognized in restructuring and asset related charges - net and
$1 million
which was recognized in sundry income - net in the company's Condensed Consolidated Statement of Operations.
|
|
(In millions)
|
Severance and Related Benefit Costs
|
Contract Termination Charges
|
Asset Related Charges
|
Total
|
||||||||
|
Balance at December 31, 2018
|
$
|
229
|
|
$
|
18
|
|
$
|
—
|
|
$
|
247
|
|
|
Charges to income from continuing operations for the three months ended March 31, 2019
|
40
|
|
—
|
|
16
|
|
56
|
|
||||
|
Payments
|
(43
|
)
|
(7
|
)
|
—
|
|
(50
|
)
|
||||
|
Asset write-offs
|
—
|
|
—
|
|
(15
|
)
|
(15
|
)
|
||||
|
Balance at March 31, 2019
|
$
|
226
|
|
$
|
11
|
|
$
|
1
|
|
$
|
238
|
|
|
(In millions)
|
Severance and Related Benefit Costs
|
Asset Related Charges
|
Total
|
||||||
|
Balance at December 31, 2018
|
$
|
54
|
|
$
|
—
|
|
$
|
54
|
|
|
Charges to income from continuing operations for the three months ended March 31, 2019
|
—
|
|
3
|
|
3
|
|
|||
|
Payments
|
(7
|
)
|
—
|
|
(7
|
)
|
|||
|
Asset write-offs
|
—
|
|
(3
|
)
|
(3
|
)
|
|||
|
Balance at March 31, 2019
|
$
|
47
|
|
$
|
—
|
|
$
|
47
|
|
|
(In millions)
|
March 31, 2019
|
December 31, 2018
|
||||
|
Accounts and notes receivable - net
|
$
|
112
|
|
$
|
201
|
|
|
Accounts payable
|
$
|
201
|
|
$
|
288
|
|
|
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
Net sales
|
$
|
115
|
|
$
|
44
|
|
|
Cost of goods sold
|
$
|
109
|
|
$
|
24
|
|
|
Sundry Income - Net
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
Interest income
|
$
|
23
|
|
$
|
28
|
|
|
Equity in earnings of affiliates - net
|
13
|
|
14
|
|
||
|
Net gain on sales of businesses and other assets
1
|
55
|
|
2
|
|
||
|
Net exchange losses
|
(32
|
)
|
(132
|
)
|
||
|
Non-operating pension and other post employment benefit credit
2
|
66
|
|
92
|
|
||
|
Miscellaneous income and expenses - net
3
|
32
|
|
43
|
|
||
|
Sundry income - net
|
$
|
157
|
|
$
|
47
|
|
|
1.
|
The three months ended March 31, 2019 includes a gain on sale of assets within the electronics and imaging product line.
|
|
2.
|
Includes non-service related components of net periodic benefit credits (costs) (interest cost, expected return on plan assets, and amortization of unrecognized loss).
|
|
3.
|
Miscellaneous income and expenses - net, includes gains related to litigation settlements and other items.
|
|
(In millions)
|
Three Months Ended March 31,
|
|||||
|
|
2019
|
2018
|
||||
|
Subsidiary Monetary Position (Losses) Gains
|
|
|
||||
|
Pre-tax exchange (losses) gains
|
$
|
(23
|
)
|
$
|
49
|
|
|
Local tax benefits
|
—
|
|
32
|
|
||
|
Net after-tax impact from subsidiary exchange (losses) gains
|
$
|
(23
|
)
|
$
|
81
|
|
|
|
|
|
||||
|
Hedging Program Losses
|
|
|
||||
|
Pre-tax exchange losses
1
|
$
|
(9
|
)
|
$
|
(181
|
)
|
|
Tax benefits
|
2
|
|
42
|
|
||
|
Net after-tax impact from hedging program exchange losses
|
$
|
(7
|
)
|
$
|
(139
|
)
|
|
|
|
|
||||
|
Total Exchange Losses
|
|
|
||||
|
Pre-tax exchange losses
|
$
|
(32
|
)
|
$
|
(132
|
)
|
|
Tax benefits
|
2
|
|
74
|
|
||
|
Net after-tax exchange losses
|
$
|
(30
|
)
|
$
|
(58
|
)
|
|
1.
|
Includes a
$50 million
foreign exchange loss for the three months ended March 31, 2018 related to adjustments to foreign currency exchange contracts as a result of U.S. tax reform.
|
|
(In millions)
|
March 31, 2019
|
December 31, 2018
|
||||
|
Cash and cash equivalents
|
$
|
3,796
|
|
$
|
4,466
|
|
|
Restricted cash
|
480
|
|
500
|
|
||
|
Total cash, cash equivalents and restricted cash
|
$
|
4,276
|
|
$
|
4,966
|
|
|
•
|
As a result of The Act, the company remeasured its U.S. federal deferred tax assets and liabilities based on the rates at which they are expected to reverse in the future, which is generally
21 percent
. In the first quarter of 2018, the company recorded a
$48 million
charge to provision for income taxes on continuing operations in the company's interim Consolidated Statements of Operations to adjust the provisional amount related to the remeasurement of the company's deferred tax balance.
|
|
•
|
In the first quarter of 2018, the company recognized a charge of
$16 million
to provision for income taxes on continuing operations in the company's interim Consolidated Statements of Operations as a result of an indirect impact of the Act related to certain inventory.
|
|
(In millions)
|
March 31,
2019 |
December 31,
2018 |
||||
|
Finished products
|
$
|
4,390
|
|
$
|
4,204
|
|
|
Semi-finished products
|
1,338
|
|
1,769
|
|
||
|
Raw materials
|
523
|
|
481
|
|
||
|
Stores and supplies
|
385
|
|
441
|
|
||
|
Total
|
$
|
6,636
|
|
$
|
6,895
|
|
|
Adjustment of inventories to a last-in, first out ("LIFO") basis
|
511
|
|
512
|
|
||
|
Total inventories
|
$
|
7,147
|
|
$
|
7,407
|
|
|
(In millions)
|
March 31, 2019
|
December 31, 2018
|
||||||||||||||||
|
|
Gross
|
Accumulated
Amortization
|
Net
|
Gross
|
Accumulated
Amortization
|
Net
|
||||||||||||
|
Intangible assets subject to amortization (Definite-lived):
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
Customer-related
|
$
|
9,310
|
|
$
|
(884
|
)
|
$
|
8,426
|
|
$
|
9,325
|
|
$
|
(744
|
)
|
$
|
8,581
|
|
|
Developed technology
1
|
4,926
|
|
(735
|
)
|
4,191
|
|
4,506
|
|
(628
|
)
|
3,878
|
|
||||||
|
Trademarks/trade names
|
1,083
|
|
(135
|
)
|
948
|
|
1,084
|
|
(114
|
)
|
970
|
|
||||||
|
Favorable supply contracts
|
493
|
|
(136
|
)
|
357
|
|
475
|
|
(111
|
)
|
364
|
|
||||||
|
Microbial cell factories
|
384
|
|
(26
|
)
|
358
|
|
386
|
|
(22
|
)
|
364
|
|
||||||
|
Other
2
|
376
|
|
(37
|
)
|
339
|
|
377
|
|
(32
|
)
|
345
|
|
||||||
|
Total other intangible assets with finite lives
|
16,572
|
|
(1,953
|
)
|
14,619
|
|
16,153
|
|
(1,651
|
)
|
14,502
|
|
||||||
|
|
|
|
|
|
|
|
||||||||||||
|
Intangible assets not subject to amortization (Indefinite-lived):
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||
|
IPR&D
1
|
100
|
|
—
|
|
100
|
|
545
|
|
—
|
|
545
|
|
||||||
|
Germplasm
3
|
6,265
|
|
—
|
|
6,265
|
|
6,265
|
|
—
|
|
6,265
|
|
||||||
|
Trademarks / trade names
|
4,740
|
|
—
|
|
4,740
|
|
4,741
|
|
—
|
|
4,741
|
|
||||||
|
Total other intangible assets
|
11,105
|
|
—
|
|
11,105
|
|
11,551
|
|
—
|
|
11,551
|
|
||||||
|
Total
|
$
|
27,677
|
|
$
|
(1,953
|
)
|
$
|
25,724
|
|
$
|
27,704
|
|
$
|
(1,651
|
)
|
$
|
26,053
|
|
|
1.
|
During the first quarter of 2019, the company announced an expanded launch of its Qrome
®
corn hybrids following the receipt of regulatory approval from China. As a result, the company reclassified the amounts from indefinite-lived IPR&D to developed technology.
|
|
2.
|
Primarily consists of sales and farmer networks, marketing and manufacturing alliances and noncompetition agreements.
|
|
3.
|
Germplasm is the pool of genetic source material and body of knowledge gained from the development and delivery stage of plant breeding. This intangible asset is expected to contribute to cash flows beyond the foreseeable future and there are no legal, regulatory, contractual, or other factors which limit its useful life.
|
|
(In millions)
|
Three Months Ended March 31, 2019
|
|
|
Operating lease cost
|
54
|
|
|
Finance lease cost
|
|
|
|
Amortization of right-of-use assets
|
35
|
|
|
Interest on lease liabilities
|
1
|
|
|
Total finance lease cost
|
36
|
|
|
Short-term lease cost
|
5
|
|
|
Variable lease cost
|
4
|
|
|
Sublease income
|
(8
|
)
|
|
Total lease cost
|
91
|
|
|
(In millions)
|
Three Months Ended March 31, 2019
|
||
|
Cash paid for amounts included in the measurement of lease liabilities:
|
|
||
|
Operating cash flows from operating leases
|
$
|
56
|
|
|
Operating cash flows from finance leases
|
$
|
1
|
|
|
Financing cash flows from finance leases
|
$
|
20
|
|
|
(In millions)
|
March 31, 2019
|
||
|
Operating Leases
|
|
|
|
|
Operating lease right-of-use assets
1
|
$
|
703
|
|
|
Current operating lease liabilities
2
|
213
|
|
|
|
Noncurrent operating lease liabilities
3
|
494
|
|
|
|
Total operating lease liabilities
|
$
|
707
|
|
|
|
|
||
|
Finance Leases
|
|
|
|
|
Property, plant, and equipment, gross
|
152
|
|
|
|
Accumulated depreciation
|
(38
|
)
|
|
|
Property, plant, and equipment, net
|
$
|
114
|
|
|
Short-term borrowings and finance lease obligations
|
43
|
|
|
|
Long-Term Debt
|
83
|
|
|
|
Total finance lease liabilities
|
$
|
126
|
|
|
1.
|
Included in other assets in the interim Condensed Consolidated Balance Sheet.
|
|
2.
|
Included in accrued and other current liabilities in the interim Condensed Consolidated Balance Sheet.
|
|
3.
|
Included in other noncurrent obligations in the interim Condensed Consolidated Balance Sheet.
|
|
Lease Term and Discount Rate
|
March 31, 2019
|
|
|
Weighted-average remaining lease term (years)
|
|
|
|
Operating leases
|
5.31
|
|
|
Finance leases
|
2.58
|
|
|
Weighted average discount rate
|
|
|
|
Operating leases
|
3.37
|
%
|
|
Finance leases
|
3.25
|
%
|
|
Maturity of Lease Liabilities at March 31, 2019
|
Operating Leases
|
Finance Leases
|
||||
|
(In millions)
|
||||||
|
2019
|
$
|
184
|
|
$
|
36
|
|
|
2020
|
171
|
|
30
|
|
||
|
2021
|
132
|
|
27
|
|
||
|
2022
|
107
|
|
27
|
|
||
|
2023
|
55
|
|
9
|
|
||
|
2024 and thereafter
|
129
|
|
6
|
|
||
|
Total lease payments
|
$
|
778
|
|
$
|
135
|
|
|
Less: Interest
|
71
|
|
9
|
|
||
|
Present value of lease liabilities
|
$
|
707
|
|
$
|
126
|
|
|
Minimum Lease Commitments at December 31, 2018
|
|||
|
(In millions)
|
|||
|
2019
|
$
|
242
|
|
|
2020
|
128
|
|
|
|
2021
|
90
|
|
|
|
2022
|
66
|
|
|
|
2023
|
44
|
|
|
|
2024 and thereafter
|
85
|
|
|
|
Total
|
$
|
655
|
|
|
Guarantees at March 31, 2019
|
Final Expiration Year
|
Maximum Future Payments
|
||
|
(In millions)
|
||||
|
Obligations for customers
1
:
|
|
|
||
|
Bank borrowings
|
2022
|
$
|
73
|
|
|
Obligations for non-consolidated affiliates
2
:
|
|
|
|
|
|
Bank borrowings
|
2019
|
166
|
|
|
|
Total guarantees
|
|
$
|
239
|
|
|
1.
|
Existing guarantees for select customers, as part of contractual agreements. The terms of the guarantees are equivalent to the terms of the customer loans that are primarily made to finance customer invoices. Of the total maximum future payments,
$72 million
had terms less than a year.
|
|
2.
|
Existing guarantees for non-consolidated affiliates' liquidity needs in normal operations.
|
|
(In millions)
|
Cumulative Translation Adjustment
1
|
Derivative Instruments
|
Pension Benefit Plans
|
Other Benefit Plans
|
Total
|
||||||||||
|
2018
|
|
|
|
|
|
||||||||||
|
Balance January 1, 2018
|
$
|
(454
|
)
|
$
|
(2
|
)
|
$
|
128
|
|
$
|
(53
|
)
|
$
|
(381
|
)
|
|
Other comprehensive income before reclassifications
|
957
|
|
12
|
|
4
|
|
—
|
|
973
|
|
|||||
|
Amounts reclassified from accumulated other comprehensive loss
|
—
|
|
(1
|
)
|
—
|
|
—
|
|
(1
|
)
|
|||||
|
Net other comprehensive income
|
957
|
|
11
|
|
4
|
|
—
|
|
972
|
|
|||||
|
Balance March 31, 2018
|
$
|
503
|
|
$
|
9
|
|
$
|
132
|
|
$
|
(53
|
)
|
$
|
591
|
|
|
|
|
|
|
|
|
||||||||||
|
2019
|
|
|
|
|
|
|
|
|
|
|
|||||
|
Balance January 1, 2019
|
$
|
(1,966
|
)
|
$
|
(26
|
)
|
$
|
(590
|
)
|
$
|
79
|
|
$
|
(2,503
|
)
|
|
Other comprehensive (loss) income before reclassifications
|
(68
|
)
|
4
|
|
(7
|
)
|
—
|
|
(71
|
)
|
|||||
|
Amounts reclassified from accumulated other comprehensive (loss) income
|
—
|
|
(3
|
)
|
1
|
|
—
|
|
(2
|
)
|
|||||
|
Net other comprehensive (loss) income
|
(68
|
)
|
1
|
|
(6
|
)
|
—
|
|
(73
|
)
|
|||||
|
Balance March 31, 2019
|
$
|
(2,034
|
)
|
$
|
(25
|
)
|
$
|
(596
|
)
|
$
|
79
|
|
$
|
(2,576
|
)
|
|
1.
|
The cumulative translation adjustment gain for the three months ended March 31, 2018 was primarily driven by the weakening of the U.S. Dollar ("USD") against the European Euro ("EUR"), as well as the Danish Kroner. The cumulative translation adjustment loss for the three months ended March 31, 2019 was primarily driven by strengthening of the USD against the EUR and the Brazilian Real.
|
|
(In millions)
|
Three Months Ended March 31,
|
|||||
|
|
2019
|
2018
|
||||
|
Derivative instruments
|
$
|
(3
|
)
|
$
|
(4
|
)
|
|
Pension benefit plans - net
|
(7
|
)
|
(2
|
)
|
||
|
Provision for income taxes related to other comprehensive loss items
|
$
|
(10
|
)
|
$
|
(6
|
)
|
|
(In millions)
|
Three Months Ended March 31,
|
Income Classification
|
|||||
|
|
2019
|
2018
|
|||||
|
Derivative Instruments:
|
$
|
(4
|
)
|
$
|
(1
|
)
|
(1)
|
|
Tax expense
|
1
|
|
—
|
|
(2)
|
||
|
After-tax
|
$
|
(3
|
)
|
$
|
(1
|
)
|
|
|
Amortization of pension benefit plans:
|
|
|
|
||||
|
Actuarial losses
|
1
|
|
—
|
|
(3)
|
||
|
Total before tax
|
$
|
1
|
|
$
|
—
|
|
|
|
Tax benefit
|
—
|
|
—
|
|
(2)
|
||
|
After-tax
|
$
|
1
|
|
$
|
—
|
|
|
|
Total reclassifications for the period, after-tax
|
$
|
(2
|
)
|
$
|
(1
|
)
|
|
|
1.
|
Cost of goods sold.
|
|
2.
|
Provision for income taxes from continuing operations.
|
|
3.
|
These accumulated other comprehensive loss components are included in the computation of net periodic benefit (credit) cost of the company's pension and other benefit plans. See Note
15
for additional information.
|
|
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
Defined Benefit Pension Plans:
|
|
|
||||
|
Service cost
|
$
|
19
|
|
$
|
34
|
|
|
Interest cost
|
206
|
|
190
|
|
||
|
Expected return on plan assets
|
(296
|
)
|
(303
|
)
|
||
|
Amortization of unrecognized loss
|
1
|
|
—
|
|
||
|
Net periodic benefit credit
|
$
|
(70
|
)
|
$
|
(79
|
)
|
|
Other Post Employment Benefits:
|
|
|
||||
|
Service cost
|
$
|
2
|
|
$
|
2
|
|
|
Interest cost
|
23
|
|
21
|
|
||
|
Net periodic benefit cost
|
$
|
25
|
|
$
|
23
|
|
|
Notional Amounts
(In millions)
|
March 31, 2019
|
December 31, 2018
|
||||
|
Derivatives designated as hedging instruments:
|
|
|
||||
|
Commodity contracts
|
$
|
351
|
|
$
|
525
|
|
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
||
|
Foreign currency contracts
|
$
|
1,442
|
|
$
|
2,057
|
|
|
Commodity contracts
|
$
|
125
|
|
$
|
9
|
|
|
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
Beginning balance
|
$
|
(26
|
)
|
$
|
(2
|
)
|
|
Additions and revaluations of derivatives designated as cash flow hedges
|
4
|
|
12
|
|
||
|
Clearance of hedge results to earnings
|
(3
|
)
|
(1
|
)
|
||
|
Ending balance
|
$
|
(25
|
)
|
$
|
9
|
|
|
|
|
March 31, 2019
|
||||||||
|
(In millions)
|
Balance Sheet Location
|
Gross
|
Counterparty and Cash Collateral Netting
1
|
Net Amounts Included in the Interim Condensed Consolidated Balance Sheet
|
||||||
|
Asset derivatives:
|
|
|
|
|
||||||
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
|
|||||
|
Foreign currency contracts
|
Other current assets
|
$
|
58
|
|
$
|
(16
|
)
|
$
|
42
|
|
|
Total asset derivatives
|
|
$
|
58
|
|
$
|
(16
|
)
|
$
|
42
|
|
|
|
|
|
|
|
||||||
|
Liability derivatives:
|
|
|
|
|
|
|||||
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
|
|
||||
|
Foreign currency contracts
|
Accrued and other current liabilities
|
$
|
17
|
|
$
|
(14
|
)
|
$
|
3
|
|
|
Total liability derivatives
|
|
$
|
17
|
|
$
|
(14
|
)
|
$
|
3
|
|
|
|
|
December 31, 2018
|
||||||||
|
(In millions)
|
Balance Sheet Location
|
Gross
|
Counterparty and Cash Collateral Netting
1
|
Net Amounts Included in the Interim Condensed Consolidated Balance Sheet
|
||||||
|
Asset derivatives:
|
|
|
|
|
||||||
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
|
|||||
|
Foreign currency contracts
|
Other current assets
|
$
|
72
|
|
$
|
(35
|
)
|
$
|
37
|
|
|
Total asset derivatives
|
|
$
|
72
|
|
$
|
(35
|
)
|
$
|
37
|
|
|
|
|
|
|
|
||||||
|
Liability derivatives:
|
|
|
|
|
|
|||||
|
Derivatives not designated as hedging instruments:
|
|
|
|
|
|
|
||||
|
Foreign currency contracts
|
Accrued and other current liabilities
|
$
|
21
|
|
$
|
(15
|
)
|
$
|
6
|
|
|
Total liability derivatives
|
|
$
|
21
|
|
$
|
(15
|
)
|
$
|
6
|
|
|
1.
|
Counterparty and cash collateral amounts represent the estimated net settlement amount when applying netting and set-off rights included in master netting arrangements between the company and its counterparties and the payable or receivable for cash collateral held or placed with the same counterparty.
|
|
|
Amount of Gain Recognized in OCI
1
- Pre-Tax
|
|||||
|
|
Three Months Ended March 31,
|
|||||
|
(In millions)
|
2019
|
2018
|
||||
|
Derivatives designated as hedging instruments:
|
|
|
||||
|
Cash flow hedges:
|
|
|
||||
|
Commodity contracts
|
$
|
8
|
|
$
|
16
|
|
|
Total derivatives designated as hedging instruments
|
8
|
|
16
|
|
||
|
Total derivatives
|
$
|
8
|
|
$
|
16
|
|
|
1.
|
OCI is defined as other comprehensive (loss) income.
|
|
|
Amount of Gain (Loss) Recognized in Income - Pre-Tax
1
|
|||||
|
(In millions)
|
Three Months Ended March 31,
|
|||||
|
|
2019
|
2018
|
||||
|
Derivatives designated as hedging instruments:
|
|
|
||||
|
Cash flow hedges:
|
|
|
||||
|
Commodity contracts
2
|
$
|
4
|
|
$
|
1
|
|
|
Total derivatives designated as hedging instruments
|
4
|
|
1
|
|
||
|
Derivatives not designated as hedging instruments:
|
|
|
||||
|
Foreign currency contracts
3
|
(9
|
)
|
(181
|
)
|
||
|
Commodity contracts
2
|
7
|
|
(3
|
)
|
||
|
Total derivatives not designated as hedging instruments
|
(2
|
)
|
(184
|
)
|
||
|
Total derivatives
|
$
|
2
|
|
$
|
(183
|
)
|
|
1.
|
For cash flow hedges, this represents the portion of the gain (loss) reclassified from accumulated OCI into income during the period.
|
|
2.
|
Recorded in cost of goods sold.
|
|
3.
|
Gain recognized in sundry income - net was partially offset by the related gain on the foreign currency-denominated monetary assets and liabilities of the company's operations. See Note
7
for additional information.
|
|
March 31, 2019
|
Significant Other Observable Inputs (Level 2)
|
||
|
(In millions)
|
|||
|
Assets at fair value:
|
|
||
|
Cash equivalents and restricted cash equivalents
1
|
$
|
2,750
|
|
|
Marketable securities
|
18
|
|
|
|
Derivatives relating to:
2
|
|
||
|
Foreign currency
|
58
|
|
|
|
Total assets at fair value
|
$
|
2,826
|
|
|
Liabilities at fair value:
|
|
||
|
Long-term debt
|
$
|
6,865
|
|
|
Derivatives relating to:
2
|
|
||
|
Foreign currency
|
17
|
|
|
|
Total liabilities at fair value
|
$
|
6,882
|
|
|
December 31, 2018
|
Significant Other Observable Inputs (Level 2)
|
||
|
(In millions)
|
|||
|
Assets at fair value:
|
|
||
|
Cash equivalents and restricted cash equivalents
1
|
$
|
3,551
|
|
|
Marketable securities
|
34
|
|
|
|
Derivatives relating to:
2
|
|
||
|
Foreign currency
|
72
|
|
|
|
Total assets at fair value
|
$
|
3,657
|
|
|
Liabilities at fair value:
|
|
||
|
Long-term debt
|
$
|
6,100
|
|
|
Derivatives relating to:
2
|
|
|
|
|
Foreign currency
|
21
|
|
|
|
Total liabilities at fair value
|
$
|
6,121
|
|
|
1.
|
Time deposits included in cash and cash equivalents and money market funds included in other current assets in the interim Condensed Consolidated Balance Sheets are held at amortized cost, which approximates fair value.
|
|
2.
|
See Note
16
for the classification of derivatives in the interim Condensed Consolidated Balance Sheets.
|
|
•
|
the assets and liabilities aligned with the company’s materials science business, including Historical DuPont’s ethylene and ethylene copolymers business, excluding its ethylene acrylic elastomers business, (“ECP”) were transferred or conveyed to separate legal entities (the “Materials Science Entities”) that were ultimately conveyed by DowDuPont to Dow;
|
|
•
|
the assets and liabilities aligned with the company’s specialty products business were transferred or conveyed to separate legal entities (“Specialty Products Entities”);
|
|
•
|
on April 1, 2019, Historical DuPont transferred and conveyed its Materials Science Entities to DowDuPont;
|
|
•
|
on May 1, 2019, Historical DuPont distributed its Special Products Entities to DowDuPont; and
|
|
•
|
on May 2, 2019, DowDuPont conveyed DAS to the company; in connection with the foregoing, the company issued additional shares of its Common Stock to DowDuPont.
|
|
•
|
Separation and Distribution Agreement - The Parties entered into an agreement that sets forth, among other things, the agreements among the Parties regarding the principal transactions necessary to effect the Distributions. It also sets forth other agreements that govern certain aspects of the Parties’ ongoing relationships after the completion of the Distributions (the "Separation and Distribution Agreement").
|
|
•
|
Tax Matters Agreement - The Parties entered into an agreement that governs their respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes.
|
|
•
|
Employee Matters Agreement - The Parties entered into an agreement that identifies employees and employee-related liabilities (and attributable assets) to be allocated (either retained, transferred and accepted, or assigned and assumed, as applicable) to the Parties as part of the Distributions and describes when and how the relevant transfers and assignments will occur.
|
|
•
|
Intellectual Property Cross-License Agreements - Dow and Corteva entered into an Intellectual Property Cross-License Agreement (the “Dow-Corteva IP Cross-License Agreement”). The Intellectual Property Cross-License Agreements set forth the terms and conditions under which the applicable Parties may use in their respective businesses, following each of the Distributions, certain know-how (including trade secrets), copyrights, and software, and certain patents and standards, allocated to another Party pursuant to the Separation and Distribution Agreement.
|
|
(in millions)
|
Amount
|
||
|
4.625% Notes due 2020
|
$
|
474
|
|
|
3.625% Notes due 2021
|
296
|
|
|
|
4.250% Notes due 2021
|
163
|
|
|
|
2.800% Notes due 2023
|
381
|
|
|
|
6.500% Debentures due 2028
|
57
|
|
|
|
5.600% Senior Notes due 2036
|
42
|
|
|
|
4.900% Notes due 2041
|
48
|
|
|
|
4.150% Notes due 2043
|
69
|
|
|
|
Total
|
$
|
1,530
|
|
|
Item 2.
|
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
|
|
•
|
the assets and liabilities aligned with the company’s materials science business, including Historical DuPont’s ethylene and ethylene copolymers business, excluding its ethylene acrylic elastomers business, (“ECP”) were transferred or conveyed to separate legal entities (the “Materials Science Entities”) that were ultimately conveyed by DowDuPont to Dow;
|
|
•
|
the assets and liabilities aligned with the company’s specialty products business were transferred or conveyed to separate legal entities (“Specialty Products Entities”);
|
|
•
|
on April 1, 2019, Historical DuPont transferred and conveyed its Materials Science Entities to DowDuPont;
|
|
•
|
on May 1, 2019, Historical DuPont distributed its Specialty Products Entities to DowDuPont; and
|
|
•
|
on May 2, 2019, DowDuPont conveyed DAS to the company; in connection with the foregoing, the company issued additional shares of its Common Stock to DowDuPont.
|
|
•
|
Separation and Distribution Agreement
- The Parties entered into an agreement that sets forth, among other things, the agreements among the Parties regarding the principal transactions necessary to effect the Distributions. It also sets forth other agreements that govern certain aspects of the Parties’ ongoing relationships after the completion of the Distributions (the "Separation and Distribution Agreement").
|
|
•
|
Tax Matters Agreement
- The Parties entered into an agreement that governs their respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes.
|
|
•
|
Employee Matters Agreement
- The Parties entered into an agreement that identifies employees and employee-related liabilities (and attributable assets) to be allocated (either retained, transferred and accepted, or assigned and assumed, as applicable) to the Parties as part of the Distributions and describes when and how the relevant transfers and assignments will occur.
|
|
•
|
Intellectual Property Cross-License Agreements
- Dow and Corteva entered into an Intellectual Property Cross-License Agreement (the “Dow-Corteva IP Cross-License Agreement”). The Intellectual Property Cross-License Agreements set
|
|
(in millions)
|
Amount
|
||
|
4.625% Notes due 2020
|
$
|
474
|
|
|
3.625% Notes due 2021
|
296
|
|
|
|
4.250% Notes due 2021
|
163
|
|
|
|
2.800% Notes due 2023
|
381
|
|
|
|
6.500% Debentures due 2028
|
57
|
|
|
|
5.600% Senior Notes due 2036
|
42
|
|
|
|
4.900% Notes due 2041
|
48
|
|
|
|
4.150% Notes due 2043
|
69
|
|
|
|
Total
|
$
|
1,530
|
|
|
|
Three Months Ended March 31,
|
|||||
|
In millions
|
2019
|
2018
|
||||
|
Net sales
|
$
|
6,288
|
|
$
|
6,699
|
|
|
|
|
|
|
|||
|
Cost of goods sold
|
$
|
4,235
|
|
$
|
4,847
|
|
|
Percent of net sales
|
67.4
|
%
|
72.4
|
%
|
||
|
|
|
|
||||
|
Research and development expenses
|
$
|
355
|
|
$
|
382
|
|
|
Percent of net sales
|
5.6
|
%
|
5.7
|
%
|
||
|
|
|
|
||||
|
Selling, general and administrative expenses
|
$
|
970
|
|
$
|
959
|
|
|
Percent of net sales
|
15.4
|
%
|
14.3
|
%
|
||
|
|
|
|
||||
|
Effective tax rate on continuing operations
|
(81.6
|
)%
|
(14.3
|
)%
|
||
|
|
|
|
||||
|
Net income (loss)
|
$
|
89
|
|
$
|
(221
|
)
|
|
|
Three Months Ended March 31,
|
|||||||
|
|
2019
|
2018
|
||||||
|
|
Net Sales
($ Billions)
|
%
|
Net Sales
($ Billions)
|
%
|
||||
|
Worldwide
|
$
|
6.3
|
|
100.0
|
$
|
6.7
|
|
100
|
|
U.S. & Canada
|
2.2
|
|
35.0
|
2.5
|
|
38
|
||
|
Europe, Middle East & Africa ("EMEA")
|
2.1
|
|
33.0
|
2.2
|
|
32
|
||
|
Asia Pacific
|
1.5
|
|
24.0
|
1.5
|
|
23
|
||
|
Latin America
|
0.5
|
|
8.0
|
0.5
|
|
7
|
||
|
(Dollars in millions)
|
March 31, 2019
|
December 31, 2018
|
||||
|
Cash, cash equivalents and marketable securities
|
$
|
3,814
|
|
$
|
4,500
|
|
|
Total debt
|
9,525
|
|
7,972
|
|
||
|
(in millions)
|
Amount
|
||
|
4.625% Notes due 2020
|
$
|
474
|
|
|
3.625% Notes due 2021
|
296
|
|
|
|
4.250% Notes due 2021
|
163
|
|
|
|
2.800% Notes due 2023
|
381
|
|
|
|
6.500% Debentures due 2028
|
57
|
|
|
|
5.600% Senior Notes due 2036
|
42
|
|
|
|
4.900% Notes due 2041
|
48
|
|
|
|
4.150% Notes due 2043
|
69
|
|
|
|
Total
|
$
|
1,530
|
|
|
Reporting Unit
|
Goodwill
|
Indefinite-Lived Intangible Assets
|
||||
|
Agriculture
|
$
|
8,859
|
|
$
|
8,237
|
|
|
Electronics and Imaging
|
4,058
|
|
480
|
|
||
|
Protection Solutions
|
5,496
|
|
260
|
|
||
|
Nutrition and Health
|
8,726
|
|
1,420
|
|
||
|
Transportation and Advanced Polymers
|
6,354
|
|
310
|
|
||
|
Packaging and Specialty Plastics
|
3,584
|
|
—
|
|
||
|
Industrial Biosciences
|
3,100
|
|
398
|
|
||
|
Clean Technologies
|
461
|
|
—
|
|
||
|
Total
|
$
|
40,638
|
|
$
|
11,105
|
|
|
Item 3.
|
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
|
|
Item 1.
|
LEGAL PROCEEDINGS
|
|
•
|
difficulties in achieving anticipated cost savings, synergies, business opportunities and growth prospects;
|
|
•
|
the possibility of faulty assumptions underlying expectations regarding the integration or separation process, including with respect to the intended tax efficient transactions;
|
|
•
|
unanticipated issues in integrating, replicating or separating information technology, communications programs, financial procedures and operations, and other systems, procedures and policies;
|
|
•
|
addressing differences in business culture and retaining key personnel;
|
|
•
|
unanticipated changes in applicable laws and regulations;
|
|
•
|
managing tax costs or inefficiencies associated with integrating the operations of the combined agriculture company and the intended tax efficient separation transactions;
|
|
•
|
coordinating geographically separate organizations;
|
|
•
|
failing to successfully optimize Corteva’s facilities footprint;
|
|
•
|
failing to take advantage of Corteva’s global supply chain;
|
|
•
|
failing to identify and eliminate duplicative programs; and
|
|
•
|
failing to otherwise integrate Historical DuPont’s or Historical Dow’s respective agriculture businesses, including their technology platforms.
|
|
Item 6.
|
EXHIBITS
|
|
|
Corteva, Inc.
|
|
|
|
(Registrant)
|
|
|
|
|
|
|
|
Date:
|
May 31, 2019
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Gregory R. Friedman
|
|
|
|
|
|
|
|
Gregory R. Friedman
|
|
|
|
Executive Vice President and
|
|
|
|
Chief Financial Officer
|
|
|
|
(As Duly Authorized Officer and
|
|
|
|
Principal Financial Officer)
|
|
Exhibit
Number
|
|
Description
|
|
|
|
|
|
|
Separation and Distribution Agreement by and among DowDuPont Inc., Dow Inc. and Corteva, Inc. (incorporated by reference to Exhibit No. 2.1 to Amendment 3 to Corteva’s Registration Statement on Form 10, filed on April 16, 2019).
|
|
|
|
|
|
|
|
Form of Amended and Restated Certificate of Incorporation of Corteva, Inc. (incorporated by reference to Exhibit No. 3.1 to Corteva’s Registration Statement on Form 10, filed on May 6, 2019).
|
|
|
|
|
|
|
|
Form of Amended and Restated Bylaws of Corteva, Inc. (incorporated by reference to Exhibit No. 3.2 to Corteva’s Registration Statement on Form 10, filed on May 6, 2019).
|
|
|
|
|
|
|
4
|
|
Corteva agrees to provide the Commission, on request, copies of instruments defining the rights of holders of long-term debt of Corteva and its subsidiaries.
|
|
|
|
|
|
|
Tax Matters Agreement by and among DowDuPont Inc., Corteva, Inc. and Dow Inc. (incorporated by reference to Exhibit No. 10.1to Amendment 3 to Corteva’s Registration Statement on Form 10, filed on April 16, 2019).
|
|
|
|
|
|
|
|
Employee Matters Agreement by and among DowDuPont Inc., Corteva, Inc. and Dow Inc. (incorporated by reference to Exhibit No. 10.2 to Amendment 3 to Corteva’s Registration Statement on Form 10, filed on April 16, 2019).
|
|
|
|
|
|
|
|
Form of Intellectual Property Cross-License Agreement by and between Corteva, Inc. and DowDuPont Inc. (incorporated by reference to Exhibit No. 10.3 to Corteva’s Registration Statement on Form 10, filed on May 6, 2019).
|
|
|
|
|
|
|
|
Intellectual Property Cross-License Agreement by and between Corteva, Inc. and Dow Inc. (incorporated by reference to Exhibit No. 10.4 to Amendment 3 to Corteva’s Registration Statement on Form 10, filed on April 16, 2019).
|
|
|
|
|
|
|
|
Form of Corteva, Inc. 2019 Omnibus Incentive Plan. (incorporated by reference to Exhibit No. 10.5 to Corteva’s Registration Statement on Form 10, filed on May 6, 2019).
|
|
|
|
|
|
|
|
Fondation de Prevoyance en Faveur du Personnel de DuPont de Nemours International SÁRL. (incorporated by reference to Exhibit No. 10.6 to Corteva’s Registration Statement on Form 10, filed on May 6, 2019).
|
|
|
|
|
|
|
|
Separation Agreement by and between E. I. du Pont de Nemours and Company and The Chemours Company (incorporated by reference to Exhibit 2.1 to E. I. du Pont de Nemours and Company's Current Report on Form 8-K (Commission file number 1-815) dated July 8, 2015).
|
|
|
|
|
|
|
|
Amendment No. 1 to Separation Agreement by and between E. I. du Pont de Nemours and Company and The Chemours Company, dated August 24, 2017 (incorporated by reference to Exhibit 2.1 to E. I. du Pont de Nemours and Company's Current Report on Form 8-K (Commission file number 1-815) dated August 25, 2017).
|
|
|
|
|
|
|
|
Tax Matters Agreement by and between E. I. du Pont de Nemours and Company and The Chemours Company (incorporated by reference to Exhibit 2.2 to E. I. du Pont de Nemours and Company's Current Report on Form 8-K (Commission file number 1-815) dated July 8, 2015).
|
|
|
|
|
|
|
|
Transaction Agreement, dated as of March 31, 2017, by and between E. I. du Pont de Nemours and Company and FMC Corporation (incorporated by reference to Exhibit 10.25 to E. I. du Pont de Nemours and Company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March 31, 2017).
|
|
|
|
|
|
|
|
The E. I. du Pont de Nemours and Company Management Deferred Compensation Plan, incorporated by reference to Exhibit 4.3 to DowDuPont Inc. Registration Statement on Form S-8 filed September 1, 2017.
|
|
|
|
|
|
|
|
The E. I. du Pont de Nemours and Company Stock Accumulation and Deferred Compensation Plan for Directors, incorporated by reference to Exhibit 4.4 to DowDuPont Inc. Registration Statement on Form S-8 filed September 1, 2017.
|
|
|
|
|
|
|
|
DuPont’s Pension Restoration Plan, as last amended effective June 29, 2015 (incorporated by reference to Exhibit 10.3 to E. I. du Pont de Nemours and Company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2015).
|
|
|
|
|
|
|
|
DuPont’s Rules for Lump Sum Payments, as last amended effective May 15, 2014 (incorporated by reference to Exhibit 10.4 to E. I. du Pont de Nemours and Company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2015).
|
|
|
|
|
|
|
|
DuPont’s Retirement Savings Restoration Plan, as last amended effective May 15, 2014. (incorporated by reference to Exhibit 10.08 to E. I. du Pont de Nemours and Company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended June 30, 2014).
|
|
|
|
|
|
|
|
DuPont’s Retirement Income Plan for Directors, as last amended January 2011 (incorporated by reference to Exhibit 10.9 to E. I. du Pont de Nemours and Company’s Quarterly Report on Form 10-Q (Commission file number 1-815) for the period ended March 31, 2012).
|
|
|
|
|
|
|
|
DuPont's Senior Executive Severance Plan, as amended and restated effective December 10, 2015 (incorporated by reference to Exhibit 10.10 to E. I. du Pont de Nemours and Company’s Annual Report on Form 10-K (Commission file number 1-815) for the year ended December 31, 2015).
|
|
|
|
|
|
|
|
Rule 13a-14(a)/15d-14(a) Certification of Corteva’s Principal Executive Officer.
|
|
|
|
|
|
|
|
Rule 13a-14(a)/15d-14(a) Certification of Corteva’s Principal Financial Officer.
|
|
|
|
|
|
|
|
Section 1350 Certification of Corteva’s Principal Executive Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
|
|
|
|
|
|
|
|
Section 1350 Certification of Corteva’s Principal Financial Officer. The information contained in this Exhibit shall not be deemed filed with the Securities and Exchange Commission nor incorporated by reference in any registration statement filed by the registrant under the Securities Act of 1933, as amended.
|
|
|
|
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
*
|
Management contract or compensatory plan or arrangement.
|
|
**
|
Upon request of the U.S. Securities and Exchange Commission, (the “SEC”), Corteva hereby undertakes to furnish supplementally a copy of any omitted schedule or exhibit to such agreement; provided, however, that Corteva may omit confidential information pursuant to Item 601(b)(10) or request confidential treatment pursuant to Rule 24b-2 of the Exchange Act for any schedule or exhibit so furnished.
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|